http://www.zibb.com/all/theme/cq/Inovio+Biomedical+Corporation Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Mon, 23 Nov 2009 18:23:46 GMTMon, 23 Nov 2009 18:23:46 GMT608831http://www.zibb.com/all/theme/cq/Inovio+Biomedical+Corporation http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://www.inovio.com/privacy.htmInovio Biomedical Corporation collects information from our website users, subscribers and other customers. In this section of our Privacy Statement, we describe the type of information we collect and how we use it to provide better services to our customers.http://www.inovio.com/privacy.htmInovio Biomedical Corporationhttp://www.medicaldaily.net/frame_linktop.asp?ID=258168Therapeutic DNA Vaccine Company Inovio Biomedical Corp. Announces ...SAN DIEGO -- Inovio Biomedical Corp. (AMEX:INO), a leader in enabling the development of therapeutic DNA vaccines for cancers and infectious diseases using ...http://www.medicaldaily.net/frame_linktop.asp?ID=258168Inovio Biomedical Corporationhttp://www.biospace.com/news_category.aspx?CategoryID=36Amgen (AMGN) (Jobs) Shares Drop, Hit by More Anemia-Drug Fallout NEW YORK, May 15 (Reuters) - Another setback for Amgen Inc.'s anemia-drug franchise sent shares of the No. 1 biotechnology company spiraling down as much as 6.http://www.biospace.com/news_category.aspx?CategoryID=36Inovio Biomedical Corporationhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=43141The application is designed to permit initial clinical testing of Tripep's proprietary DNA vaccine, ChronVac-C(R), administered using Inovio's MedPulser(R) DNA Delivery System. This combination is designed to activate a T-cell response capable of clearing hepatitis C virus.http://www.pharmacychoice.com/News/article.cfm?Article_ID=43141Inovio Biomedical Corporationhttp://www.newsrx.com/newsletters/Vaccine-Weekly/2007-06-06/42060620078VW.htmlDr. Christian H. Ottensmeier, MD, PhD, Cancer Research UK Senior Clinical Research Fellow at the University of Southampton, will present interim data at the 3rd International Conference on DNA Vaccines in Malaga, Spain, from this University of Southampton Phase I/II clinical...http://www.newsrx.com/newsletters/Vaccine-Weekly/2007-06-06/42060620078VW.htmlInovio Biomedical Corporationhttp://www.buyandhold.com/StockMgr?request=display.content&symbol=INO&ContentURL=%2Fcustom%2Fbuyandhold%2Dcom%2Fhtml%2Dnews%2Easp&symb=INOCopyright © 2007 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc. Intraday data provided by ComStock, an Interactive Data Company and subject to the Terms of Use.http://www.buyandhold.com/StockMgr?request=display.content&symbol=INO&ContentURL=%2Fcustom%2Fbuyandhold%2Dcom%2Fhtml%2Dnews%2Easp&symb=INOInovio Biomedical Corporationhttp://www.inovio.com/aboutus/inoviocorporateoverviewandhistory.htm"Immunization ranks among the most important health advances of the 20th century. With the exception of safe drinking water, vaccinology has more effectively reduced mortality than any other modality."http://www.inovio.com/aboutus/inoviocorporateoverviewandhistory.htmInovio Biomedical Corporationhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=662Inovio's DNA delivery technology will be used to deliver a therapeutic plasmid-based DNA vaccine to skeletal muscles with the aim of treating recurrent prostate cancer.http://www.pharmacychoice.com/News/article.cfm?Article_ID=662Inovio Biomedical Corporationhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=38977BIOWIRE2K SAN DIEGO--(BUSINESS WIRE)--Oct. 17, 2006--Inovio Biomedical Corporation (AMEX:INO), a late stage developer of oncology therapies and DNA vaccines using electroporation to deliver drugs and nucleic acids, announced today it has acquired from Valentis, Inc.http://www.pharmacychoice.com/News/article.cfm?Article_ID=38977Inovio Biomedical Corporationhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=12699The United States Congress appropriated the funding in the Defense Appropriations Bill for 2005. The appropriation is a continuation of the first United States Army grant received by Inovio AS in Norway last year. Inovio is working closely on this project with Dr.http://www.pharmacychoice.com/News/article.cfm?Article_ID=12699Inovio Biomedical Corporationhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=39661These data complement the results of previous studies demonstrating that electroporation using the MedPulser(R) gene delivery system was as good as or better than the gene gun in inducing humoral immune responses in mice.http://www.pharmacychoice.com/News/article.cfm?Article_ID=39661Inovio Biomedical Corporationhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=41571Under the terms of the agreement, Inovio will receive from VGX an upfront license fee and payments based on successful completion of clinical and regulatory milestones.http://www.pharmacychoice.com/News/article.cfm?Article_ID=41571Inovio Biomedical Corporationhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=52963DNA Delivery Technology Published in Journal of Virology Business Editors/Health/Medical Writers SAN DIEGO--(BUSINESS WIRE)--March 26, 2007--Inovio Biomedical Corp.http://www.pharmacychoice.com/News/article.cfm?Article_ID=52963Inovio Biomedical Corporationhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=58187The results demonstrated safety, tolerability and significantly higher antibody responses for patients who received the vaccine with Inovio's delivery system versus those who were treated without it.http://www.pharmacychoice.com/News/article.cfm?Article_ID=58187Inovio Biomedical Corporationhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=10314/8/05 - Inovio Biomedical and University of Southampton collaboration: Initiation of Phase I/II clinical trial in patients with recurrent prostate cancer.http://www.pharmacychoice.com/News/article.cfm?Article_ID=1031Inovio Biomedical Corporationhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=3730This option exercise is provided for under a 2004 license and research collaboration agreement between Merck and Genetronics Biomedical Corporation, now Inovio Biomedical Corporation, and brings the total number of antigens licensed by Merck to three.http://www.pharmacychoice.com/News/article.cfm?Article_ID=3730Inovio Biomedical Corporationhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=53757SAN DIEGO--(BUSINESS WIRE)--April 5, 2007--Inovio Biomedical Corp. (AMEX:INO), which is focused on the development of DNA-based immunotherapy products and a novel tumor ablation therapy, announced today that its Executive Director of Corporate Development, Dr.http://www.pharmacychoice.com/News/article.cfm?Article_ID=53757Inovio Biomedical Corporationhttp://www.newsrx.com/newsletters/Vaccine-Weekly/2007-06-06/42060620077VW.html',250)" onMouseout="hideddrivetip()">DNA vaccine, ChronVac-C(R), administered using Inovio's MedPulser(R) DNA Deoxyribonucleic acid. The molecules inside cells that carry genetic information and pass it from one generation to the next.http://www.newsrx.com/newsletters/Vaccine-Weekly/2007-06-06/42060620077VW.htmlInovio Biomedical Corporationhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=49037SAN DIEGO--(BUSINESS WIRE)--Feb. 14, 2007--Inovio Biomedical Corp. (AMEX:INO), which is focused on the development of DNA vaccines and a novel tumor ablation therapy, announced today that the US Patent and Trademark Office has issued to Genetronics, Inc.http://www.pharmacychoice.com/News/article.cfm?Article_ID=49037Inovio Biomedical Corporationhttp://www.newsrx.com/newsletters/Vaccine-Weekly/2007-07-04/420704200711VW.htmlTumors may be benign (not cancerous), or malignant (cancerous). Also called neoplasm.',250)" onMouseout="hideddrivetip()">tumor response rate The percentage of patients whose cancer shrinks or disappears after treatment.',250)" onMouseout="hideddrivetip()">response rate.http://www.newsrx.com/newsletters/Vaccine-Weekly/2007-07-04/420704200711VW.htmlInovio Biomedical Corporationhttp://www.newsrx.com/newsletters/Vaccine-Weekly/2007-11-14/421114200760VW.htmlAvtar Dhillon, president and CEO, will present a corporate overview on Inovio at two upcoming conferences as follows: -0- *T BIOCOM Investor Conference Thursday, November 1st 10:00 a.m.http://www.newsrx.com/newsletters/Vaccine-Weekly/2007-11-14/421114200760VW.htmlInovio Biomedical Corporation